CHEK2 and breast carcinoma: Biallelic loss of CHEK2 has been associated with significantly higher breast cancer risks than heterozygote carriership in earlier studies [34, 35], and indeed, bilateral breast cancer was seen in six out of the 7 women with two PVs in CHEK2.